Abstract
Fimasartan is the ninth angiotensin receptor blocker to be developed. However, it has not yet been evaluated for reno-protective effects in hypertensive diabetic chronic kidney disease (CKD). The target blood pressure (BP) for hypertensive diabetic CKD is also a controversial topic. This trial was designed to assess the reno-protective effects of fimasartan compared to those of losartan as a primary outcome. This study also compares the two drugs with regard to cardiovascular and renal outcomes in accordance with target systolic BP (SBP) (as secondary outcomes). This study is a prospective, phase III, randomized, double-blind, active-controlled, non-inferiority, four-parallel group, dose-titration, multicenter trial. We recruit patients with hypertensive diabetic CKD with overt proteinuria. Participants will be randomized into four groups (1:1:1:1): fimasartan standard SBP control (SBP < 140 mmHg); fimasartan strict SBP control (SBP < 130 mmHg); losartan standard SBP control; and losartan strict SBP control. After 24 weeks, all individuals are treated with fimasartan for an additional 120 weeks in an open-label design, maintaining their assigned SBP control groups as randomized. The primary endpoint is the rate of change in pro...Continue Reading
References
Nov 15, 1995·Annals of Internal Medicine·J C PetersonJ L Seifter
Mar 31, 1994·The New England Journal of Medicine·S KlahrG Striker
Nov 1, 1996·Kidney International·J A BreyerT Berl
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Dec 4, 2003·Annals of Internal Medicine·Kristian WachtellPeter Aurup
Feb 19, 2004·JAMA : the Journal of the American Medical Association·Caroline S FoxDaniel Levy
May 20, 2004·Kidney International·Dick de ZeeuwBarry M Brenner
Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
May 3, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jan GalleUNKNOWN VIVALDI investigators
May 23, 2008·Kidney International·George BakrisUNKNOWN AMADEO Study Investigators
Sep 8, 2010·The New England Journal of Medicine·Lawrence J AppelUNKNOWN AASK Collaborative Research Group
Mar 12, 2011·Journal of Cardiovascular Pharmacology·SoJeong YiKyung-Sang Yu
Jan 24, 2012·Bioorganic & Medicinal Chemistry Letters·Tae Woo KimJae Yeol Lee
Oct 11, 2012·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Hideki HirakataUNKNOWN Japanese Society for Dialysis Therapy
Jan 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeong Bae ParkEun Joo Cho
Jun 19, 2013·European Heart Journal·Giuseppe ManciaDavid A Wood
Dec 18, 2013·The Journal of Clinical Hypertension·Michael A WeberStephen B Harrap
Dec 20, 2013·JAMA : the Journal of the American Medical Association·Paul A JamesEduardo Ortiz
Jan 1, 2013·Kidney International Supplements
Mar 5, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tahsin F KelliciThomas Mavromoustakos